Eli Lilly’s Taltz (ixekizumab) Receives the US FDA’s Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Eli Lilly’s Taltz (ixekizumab) Receives the US FDA’s Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Shots:

  • The approval is based on P-III study assessing Taltz (20mg for <25kg/40mg for 25-50kg/80 mg for >50 kg @12wks., with 40/80/160mg starting doses, respectively) vs PBO in 171 patients aged 6-18 yrs. with mod. to sev. PsO who are candidates for systemic therapy or phototherapy
  • The P-III study results: patients achieving PASI 75 (89% vs 25%); patients achieving sPGA 0,1 (81% vs 11%); safety profile in pediatric patients is consistent with adult patients
  • Taltz is a mAb targeting IL-17A cytokine, inhibiting its interaction with the IL-17 receptor and has received its first FDA’s approval in Mar’2016 for mod. to sev. PsO and for active PsA & AS in adults in Dec’2017 & Aug’2019 respectively

Click here ­to­ read full press release/ article | Ref: Eli Lilly  | Image: Pinterest